The United Laboratories (TUL) and Novo Nordisk Enter Exclusive License Agreement for UBT251
Shots:
- TUL has granted Novo Nordisk exclusive global rights to develop, manufacture & market UBT251 in fields across obesity, T2D, & other diseases (excl. Mainland China, Hong Kong, Macau, & Taiwan)
- As per the deal, TUL will receive $200M upfront & ~$1.8B in milestones, plus net sales-based tiered royalties, with it retaining rights in Novo Nordisk’s non-licensed areas
- UBT251 (GLP-1/GIP/glucagon receptor agonist) was assessed in P-Ib trial in China, evaluating its multiple SC formulations (QW for 12wks.) in 36 overweight or obese pts across 3 cohorts (1mg, 1mg/3mg, 1mg/3mg/6mg). In the highest-dose group, completers saw 15.1% weight loss vs 1.5% with PBO & TUL has now initiated P-II trial in China
Ref: Globenewswire | Image: Novo Nordisk & United Laboratories
Related News:- Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
